Paraneoplastic Antigens as Biomarkers for Early Detection and Prediction of Recurrence of the Ovarian Cancer

Michael A Tainsky

Abstract

Paraneoplastic Antigens as Biomarkers for Early Detection and Prediction of Recurrence of the Ovarian Cancer

Routine disease monitoring of ovarian cancer patients is generally recommended by gynecologic oncologists for women from high-risk families and for ovarian cancer patients after the completion of primary surgery and first-line chemotherapeutic treatments. The recurrence is determined by measuring the level of serum CA125, one of the most extensively used tumor biomarkers in standard clinical practice for disease surveillance. Numerous studies have shown the role of tumor autoantibodies as biomarkers for ovarian cancer diagnosis and its recurrence. These autoantibodies to tumor-associated antigens (TAAs) arise due to the generation of humoral immune response before evidence of clinical symptoms in cancer patients.

Author(s):

Michael A Tainsky

Abstract | PDF

Share this